

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca/terms-of-use</u> and according to acceptable standards of care.

PROTOCOL CODE: GIGAVCCT

Page 1 of 2

DOCTOR'S ORDERS	Ht	cm	Wt	kg BSA	m²	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form						
DATE: To be give	ven:			Cycle #:		
Date of Previous Cycle:						
Delay treatment week(s)						
CBC & Diff, creatinine day of treatment						
May proceed with doses as written if within 96 hours ANC <u>greater than or equal to</u> 1.5 x 10 ⁹ /L, platelets <u>greater than</u> or equal to 100 x 10 ⁹ /L, and creatinine clearance greater than or equal to 60 mL/minute						
Dose modification for: Hematology Other Toxicity						
Proceed with treatment based on blood work from						
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm						
dexamethasone B mg or 12 mg (select one) PO 30 to 60 minutes prior to chemotherapy on Day 1 and select ONE of the following:						
aprepitant 125 mg PO 30 to 60 minutes prior to chemotherapy on Day 1						
ondansetron 8 mg PO 30 to 60 minutes prior to chemotherapy on Day 1						
netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to chemotherapy on Day 1						
☐ Other:						
PRE-HYDRATION:						
1000 mL NS over 1 hour pre-CISplatin						
TREATMENT:						
CISplatin 80 mg/m ² x BSA = mg						
Dose Modification:% =mg/m ² x BSA =mg						
IV in 500 mL NS with 20 mEq potassium chloride, 1 g magnesium sulphate, 30 g mannitol over 1 hour						
Cycle 1 Only:						
trastuzumab 8 mg/kg x kg =mg IV in 250 mL NS over 1 hour 30 minutes.						
Observe for 1 hour post infusion**						
Pharmacy to select trastuzumab brand as per Provincial	Systemic The	rapy Policy	' III-190			
Drug Brand (Pharmacist to complete.	. Please print.)	Pharma	cist Initial and Date		
trastuzumab						
acetaminophen 325 to 650 mg PO PRN for headache and rigors						
capecitabine 1000 mg/m² x BSA x (%) =mg PO BID x 14 days						
(refer to <u>Capecitabine Suggested Tablet Combination Table</u> for dose rounding)						
DOCTOR'S SIGNATURE: SIGNATURE:						
DOCTOR'S SIGNATURE:				SIGNATU	KE:	
				UC:		



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca/terms-of-use</u> and according to acceptable standards of care.

PROTOCOL CODE: GIGAVCCT

Page 2 of 2

DATE:						
TREATMENT:						
Cycle 2 trastuzumab 6 mg/kg x kg = mg IV in 250 mL NS over 1 hour every three weeks x (Observe for 30 minutes post infusion**						
Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190 Drug Brand (Pharmacist to complete. Please print.) Pharmacist Ir	Pharmacist Initial and Date					
trastuzumab						
Cycle 3 and Subsequent: trastuzumab 6 mg/kg x kg = mg IV in 250 mL NS over 30 minutes every three weeks x Cycle(s Observe for 30 minutes post infusion**. Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190						
	nitial and Date					
trastuzumab						
acetaminophen 325 to 650 mg PO PRN for headache and rigors capecitabine 1000 mg/m ² x BSA x (%) =mg PO BID x 14 days (refer to <u>Capecitabine Suggested Tablet Combination Table</u> for dose rounding)						
RETURN APPOINTMENT ORDERS						
 Return in three weeks for Doctor and Cycle Return in weeks for Doctor and Cycle Last Cycle. Return in three weeks for GIGAVTR (to continue single agent trastuzumab) 						
CBC & Diff, creatinine, total bilirubin, ALT prior to each cycle						
If clinically Indicated: CEA CA 19-9 ECG MUGA scan or chocardiogram alkaline phosphatase albumin GGT sodium potassium INR weekly INR prior to each cycle Other tests: Weekly nursing assessment for (specify concern):						
DOCTOR'S SIGNATURE:	SIGNATURE:					
	UC:					